Topic 4: Recognize Escalation Signals
Escalation does not automatically mean a specific drug. It means acknowledging that the current plan is not meeting the patient’s needs and deciding what should change: diagnosis confirmation, adherence review, treatment optimization, advanced medical therapy, procedural care, or specialist coordination.
Signals that should prompt active reassessment
- Persistent inflammatory lesions or little disease-free time between flares
- Increasing flare frequency, lesion number, involved regions, or bilateral disease
- New drainage, residual scarring, a new tunnel, or extension of an existing tunnel
- Inadequate control after an appropriate trial of conventional therapy
- Repeated acute-care visits or repeated antibiotic courses without durable control
- Moderate or greater pain, quality-of-life impairment, or functional limitation
- A high-risk site or phenotype, rapidly progressive disease, or important comorbidity
North American guidance supports matching therapy to disease severity, treatment response, and the presence of inflammatory or structural disease. A 2025 US expert algorithm updates this approach for a changing treatment landscape and emphasizes that medical and procedural strategies may need to be combined.58
| US prescribing context: For a predominantly US audience, any drug-specific recommendation must be checked against current FDA-approved labeling, safety requirements, and applicable US guidance at the time of publication. International evidence may inform the clinical discussion but should not be presented as controlling US prescribing practice. |
This content is sponsored but developed independently with Steven Daveluy, MD, Dermatologist.